Cambridge, United States
HC Bioscience, Inc., founded in 2021, is pioneering advancements in the biotechnology landscape with its focus on tRNA-based therapeutics. Known for its slogan, "A New Era of Protein Engineering with tRNA Therapeutics," the company is tackling protein dysfunction by leveraging first-in-class therapies.
Positioned at the intersection of Biotechnology, Health Care, and Life Sciences, HC Bioscience is dedicated to developing solutions for genetically defined diseases. Notably, their approach offers the versatility to address numerous diseases with a single therapy, independent of gene type or mutation location.
Operating out of the United States, the company has already attracted interest from notable investors. Most recently, CureDuchenne Ventures provided an early VC investment on 01 February 2023. This reflects growing confidence in their innovative therapies for targeted protein editing.
